PERKINELMER INC - PKI STOCK NEWS

PerkinElmer, Inc. (NYSE: PKI) has launched the Vega® imaging system, an innovative automated ultrasound platform aimed at enhancing preclinical research in cancer, liver and kidney diseases, and cardiology. The system allows for hands-free operation and high-throughput scanning, improving research efficiency. Key features include advanced imaging modes for better visualization of diseases and therapies. This technology was acquired through PerkinElmer's purchase of SonoVol, Inc. The company recently reported revenues near $5 billion in 2021, supporting its position in the S&P 500.

PerkinElmer has launched two innovative no-wash assay kits, HTRF® and AlphaLISA®, aimed at detecting and quantifying CHO HCP impurities in biopharmaceutical manufacturing. These kits enhance efficiency by streamlining workflows and improving sensitivity compared to traditional methods. The assays are designed for high-throughput capabilities with the ability to process samples in 384-well plates, addressing challenges in biomanufacturing. This development supports PerkinElmer's comprehensive solutions for drug development from discovery to quality control.

PerkinElmer, a leader in health innovation, will present at the Cowen 42nd Annual Health Care Conference and the Barclays Global Healthcare Conference. The Cowen conference is scheduled for March 7, 2022, with Jamey Mock, CFO, presenting at 10:30 a.m. ET. Following this, Prahlad Singh, CEO, will present at the Barclays conference on March 15, 2022, at 1:30 p.m. ET in Miami. Both presentations will provide insights on the company's strategic priorities, with live audio webcasts available on their website, where replays will also be accessible for 90 days post-event.

PerkinElmer, a leader in health innovation, will present at Citi’s Virtual Healthcare Conference on February 24, 2022, at 8:45 a.m. ET. CEO Prahlad Singh will discuss the company's strategic priorities. Interested participants can register here. A live webcast will also be available on the Investors section of the company’s website, with a replay accessible for 90 days post-event.

PerkinElmer reported $5.0 billion in revenue for 2021 and operates in 190 countries.

EUROIMMUN, a subsidiary of PerkinElmer (NYSE:PKI), announced the inclusion of its Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) test in the CDC's pre-vaccination screening for the Dengvaxia vaccine. This test is crucial for ensuring that children aged 9-16, who have a laboratory-confirmed previous dengue infection, can access the vaccine in dengue-endemic areas. In 2019, dengue cases reached record levels, emphasizing the need for effective diagnostic solutions. The assay focuses on virus-specific antibodies, enabling better vaccination strategies against dengue disease.

PerkinElmer reported 4Q 2021 revenue of $1.36 billion, reflecting a 1% reported growth but a -9% organic growth. GAAP EPS from continuing operations was $1.41, down from $3.38 in 4Q 2020. For the full year, GAAP revenue reached $5.067 billion, up from $3.783 billion in 2020, boasting a 32% increase. The company also announced its 2022 guidance, projecting first-quarter revenue between $1.17-$1.19 billion and full-year revenue of $4.42-$4.50 billion.

The Board of Directors of PerkinElmer (NYSE: PKI) announced a quarterly dividend of $0.07 per share on January 27, 2022. The dividend will be payable on May 13, 2022 to shareholders on record by the close of business on April 22, 2022. PerkinElmer reported approximately $3.8 billion in revenue for 2020 and employs over 16,000 people globally, serving customers in 190 countries.

PerkinElmer, Inc. (NYSE: PKI) anticipates exceeding its fourth quarter 2021 revenue and earnings guidance. Expected adjusted earnings per share is at least $2.40, with fourth quarter COVID-related revenue projected at approximately $320 million. Non-COVID organic growth for the same quarter is estimated at 10%, leading to an annual growth of roughly 16%. Total projected revenues for 2021 are around $5.0 billion, with substantial contributions from both Diagnostics and Discovery segments.

PerkinElmer (NYSE: PKI) is set to present virtually at the J.P. Morgan Healthcare Conference on January 11, 2022, at 11:15 a.m. ET. The company's CEO, Prahlad Singh, will discuss strategic priorities and provide an update on operations. A live audio webcast will be accessible via the provided link, and a replay will be available on the PerkinElmer Investor Relations website for 30 days post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion and employs over 16,000 staff globally, serving customers in 190 countries.